Gland Pharma Limited (GLAND.NS)
INR 1764.95
(0.06%)
INR 1764.95
(0.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 56.64 Billion INR | 56.29% |
| 2022 | 36.24 Billion INR | -17.32% |
| 2021 | 43.84 Billion INR | 28.06% |
| 2020 | 34.23 Billion INR | 33.12% |
| 2019 | 25.71 Billion INR | 29.03% |
| 2018 | 19.93 Billion INR | 26.14% |
| 2017 | 15.8 Billion INR | 6.82% |
| 2016 | 14.79 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 14.01 Billion INR | -8.83% |
| 2024 Q2 | 14.05 Billion INR | 0.29% |
| 2023 FY | 56.64 Billion INR | 56.29% |
| 2023 Q2 | 13.73 Billion INR | 13.63% |
| 2023 Q3 | 15.45 Billion INR | 12.5% |
| 2023 Q1 | 12.08 Billion INR | 53.97% |
| 2023 Q4 | 15.37 Billion INR | -0.5% |
| 2022 Q1 | 8.56 Billion INR | -21.13% |
| 2022 FY | 36.24 Billion INR | -17.32% |
| 2022 Q4 | 7.85 Billion INR | -16.34% |
| 2022 Q3 | 9.38 Billion INR | -10.16% |
| 2022 Q2 | 10.44 Billion INR | 21.88% |
| 2021 FY | 43.84 Billion INR | 28.06% |
| 2021 Q4 | 10.86 Billion INR | 2.17% |
| 2021 Q3 | 10.63 Billion INR | -1.59% |
| 2021 Q2 | 10.8 Billion INR | -6.36% |
| 2021 Q1 | 11.53 Billion INR | 35.99% |
| 2020 Q1 | 8.63 Billion INR | 50.44% |
| 2020 Q2 | 8.31 Billion INR | -3.67% |
| 2020 Q3 | 8.59 Billion INR | 3.36% |
| 2020 FY | 34.23 Billion INR | 33.12% |
| 2020 Q4 | 8.48 Billion INR | -1.27% |
| 2019 FY | 25.71 Billion INR | 29.03% |
| 2019 Q4 | 5.73 Billion INR | -11.17% |
| 2019 Q3 | 6.45 Billion INR | 0.0% |
| 2019 Q1 | 6.6 Billion INR | 0.0% |
| 2018 FY | 19.93 Billion INR | 26.14% |
| 2017 FY | 15.8 Billion INR | 6.82% |
| 2016 FY | 14.79 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott India Limited | 58.48 Billion INR | 3.149% |
| Cipla Limited | 257.74 Billion INR | 78.022% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.53 Billion INR | -64.019% |
| Kopran Limited | 6.14 Billion INR | -821.705% |
| Marksans Pharma Limited | 21.77 Billion INR | -160.159% |
| NGL Fine-Chem Limited | 3.38 Billion INR | -1572.547% |
| Pfizer Limited | 21.93 Billion INR | -158.289% |
| Sanofi India Limited | 28.51 Billion INR | -98.685% |
| SMS Pharmaceuticals Limited | 7.09 Billion INR | -698.677% |
| TTK Healthcare Limited | 7.52 Billion INR | -652.493% |